These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 974989)

  • 21. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
    Kalghatgi KK; Moroson BA; Horváth C; Bertino JR
    Cancer Res; 1979 Sep; 39(9):3441-5. PubMed ID: 476673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
    Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
    J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative distribution of Baker's antifolate (NSC 139105) in rat tissues after subcutaneous and intravenous injections.
    Yang BC; Ho DH; Brown NS; Benjamin RS; Bodey GP
    J Med; 1980; 11(5-6):413-24. PubMed ID: 6962827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer.
    Cummings FJ; Gelman R; Skeel RT; Kuperminc M; Israel L; Colsky J; Tormey D
    Cancer; 1981 Aug; 48(3):681-5. PubMed ID: 6166363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
    Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local toxicity from iv administration of Baker's antifol.
    Krasnow SH; Patterson RH; Fischmann B; Eisenberger MA; Johnston-Early A; Citron ML; Cohen MH
    Cancer Treat Rep; 1985 Jun; 69(6):735-6. PubMed ID: 4016783
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
    Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1987 Sep; 71(9):865-7. PubMed ID: 3476203
    [No Abstract]   [Full Text] [Related]  

  • 30. Baker's antifol in children with therapy-resistant solid tumors: a Southwest Oncology Group Study.
    Nitschke R; Morgan SK; Land VJ
    Cancer Treat Rep; 1981; 65(7-8):725-7. PubMed ID: 7248990
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
    Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
    Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of pyrazofurin.
    Salem PA; Bodey GP; Burgess MA; Murphy WK; Freireich EJ
    Cancer; 1977 Dec; 40(6):2806-9. PubMed ID: 589556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Vogl SE; Lanham R; Kaplan BH
    Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
    Ratliff AF; Wilson J; Hum M; Marling-Cason M; Rose K; Winick N; Kamen BA
    J Clin Oncol; 1998 Apr; 16(4):1458-64. PubMed ID: 9552052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
    Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
    Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.